Rx Propellant, India’s leading science and R&D infrastructure platform established by Actis and backed by General Atlantic, has announced a US$100 million investment to develop a large‑format life sciences campus in Genome Valley, Hyderabad. The project underscores the company’s long‑term commitment to strengthening India’s life sciences ecosystem and supporting the country’s growing R&D and CRDMO demand.
Spread across ~12 acres, the integrated campus will deliver more than 1 million sq. ft. of advanced laboratory infrastructure in phases over the next six years. Designed to global standards, the development will cater to both domestic and international corporations seeking scalable, compliant, and institutional‑grade laboratory spaces. The campus will offer flexible leasing formats, including built‑to‑suit options, supported by resilient electromechanical services and robust design.
Ashish Singh, CEO & Managing Director, Rx Propellant, said: “India’s life sciences sector is entering a phase of decisive scale‑up, and infrastructure must evolve in parallel to support this growth. This investment reflects our conviction in Genome Valley as a long‑term anchor for global and domestic R&D. With our 1GV and 3GV campuses already 100% leased, sustained demand provides a strong foundation for our next phase of growth.”
Beyond Hyderabad, Rx Propellant is also developing the Navi Mumbai Research District (NMRD), spread over 16 acres, planned as Mumbai’s largest cohesive ecosystem for science and research. Together, these projects reflect the company’s strategy of creating institutional‑quality science and R&D infrastructure across India’s most important innovation clusters.
Sustainability remains a core pillar of Rx Propellant’s development philosophy. All campuses are designed to meet LEED and IFC EDGE certification standards, ensuring long‑term resource efficiency and reduced environmental impact.
Brian Chinappi, Managing Director and Global Head of Real Estate & Data Centers at Actis, added: “High‑quality physical infrastructure is foundational to building globally competitive life sciences ecosystems. Expanding Rx Propellant’s footprint in Genome Valley is a strategic step toward building a network of world‑class campuses in India that can support companies at every stage of their growth journey.”
Genome Valley has evolved over two decades into India’s most established life sciences cluster, anchored by pharmaceutical and biotechnology companies, research institutions, and specialised infrastructure. With its deep talent pool and strong public‑private investment, the region is positioned as a preferred destination for innovation‑driven enterprises. Rx Propellant’s upcoming campus is expected to further strengthen Hyderabad’s role as a global R&D hub.
